🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to health experts.

An International Health Concern

Cases of gonorrhoea are increasing globally, with figures suggesting in excess of 82 million instances each year. Particularly high rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary advancement in the face of rising global incidence, the spread of superbugs and the extremely scarce treatment choices currently available.”

Public health authorities are particularly alarmed about the rise in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Treatment Options Receive Clearance

One new antibiotic, also known as a brand name, was cleared by the US FDA in recent days for combating gonorrhoea. This infection can lead to major issues, including infertility. Scientists anticipate that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GSK, was also approved in the same week. This treatment, which is employed against urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to see it through.

“This authorization signifies a significant shift in the treatment of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Clinical Trial Data and Global Access

Based on results detailed in a prominent scientific publication, zoliflodacin cured more than 90% of genital gonorrhoea infections. This places it at an comparable level with the typical regimen, which combines an injection and a pill. The research involved over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the ability to register and commercialise the drug in numerous low-income and middle-income countries.

Clinicians on the front lines have voiced positive views. Access to a easy-to-administer therapy of this kind is described as a "revolutionary step" for managing the epidemic. This is considered crucial to lessen the impact of the disease for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.